Skip to the content
Menu
Abstract

The multiplex technology allows multiple measurements of circulating biomarkers with high throughput, precision and accuracy. Using custom-made multiplex MSD panels, we will measure a range of biomarkers involved in metabolism, oxidation, inflammation, cardiac load, fibrosis, coagulation, calcium metabolism or kidney function as shown. The biomarkers are selected based on an a priori hypothesis of each having high subsegments category defining and/or prognosis predicting
potential.


Formål

1. To validate, refine and/or redefine the proposed novel T2D subsegments (SS)
2. To characterize in-depth the etiologies and disease mechanisms of distinct T2D SS
3. To examine treatment responses, disease trajectories and outcomes over time in different T2D SSs


Studiepopulation

Our main cohort will consist of the current 9,184 (as of September 2020) DD2 patients with a new T2D diagnosis at enrolment (median age 61 years, 58% male). The median follow-up will be 6.5 years end 2020.


Artikler

Finansiering

Novo Nordisk Fonden

Hvad er DD2

Få et overblik på 2 minutter